Trinity Bio ADR (TRIB) Stock Price, Quote & News

Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles,...

Industry: Medical Devices

Sector: Healthcare

Phone: 353 1 276 9800

Fax: 353 1 276 9888

Website: www.trinitybiotech.com

Address:

IDA Business Park, Bray, Ireland

kd1313 Sep. 12 at 1:27 PM

$TRIB wild to think that Perceptive Advisors is willing to allow share dilution and the inevitable stock split.

0 · Reply

LosersMakeMillions Sep. 12 at 12:35 PM

$TRIB

0 · Reply

EDayTrade Sep. 12 at 12:00 PM

$TRIB 😡😩😡

0 · Reply

Clydagh Sep. 12 at 9:11 AM

$TRIB for those who dont know the history. . The Waveform CGM was developed by Bayer who sold that business but continued to work with the new owner. Key patents were licensed to Dexcom on a non-exclusive basis. Dexcom are now a massive CGM player. Bayer and Waveform developed a new CGM that proved better than Dexcom in trials but was not launched. TRIB bought the CGM assets of Waveform in Jan 2024 with a plan to enhance the technology The deal came with a planned partnership with Bayer to sell CGM into China (where diabetes is a massive and growing problem). Trib signed a Letter of Intent with Bayer - a formal partnership was supposed to follow. So far no partnership has been announced and the recently release Annual Report makes no reference to the Letter of Intent, CGM partnerships or Bayer in relation to CGM TRIB still insist CGM is their biggest opportunity with a broader suite of wearable biosensors to follow. Trib continue to pour cash in CGM R&D - hence the rights issue.

1 · Reply

kd1313 Sep. 12 at 7:32 AM

$TRIB

1 · Reply

kd1313 Sep. 11 at 9:00 AM

$TRIB share dilution is going to be approved. Standby for the r/s.

1 · Reply

Think_Bigly Sep. 11 at 4:24 AM

$TRIB Trinity Biotech Reaches Profitability 'continued international roll out of its most recently launched products including: its upgraded diabetes care HbA1c testing product, and additional launch countries for its TrinScreen HIV tests.** [5-10M qty each produce cost effectiveness.] https://finance.yahoo.com/news/trinity-biotech-reaches-profitability-inflection-130000578.html

0 · Reply

m1ster_leboeuf Sep. 10 at 9:55 PM

$TRIB Do it.. boom.

0 · Reply

Think_Bigly Sep. 10 at 8:29 PM

$TRIB Sell IMMCo -$175M-$200M Pg 9, scroll down. "We have also launched a strategic realignment review of our businesses in partnership with Barclays Bank. This process, is expected to make significant progress by the end of 2025 and may generate material capital proceeds that can be potentially used to reduce debt and support investment, including CGM investment.." https://trinitybiotech.com/wp-content/uploads/2025/09/Trinity-Biotech-plc-Annual-Report-2024.pdf

0 · Reply

Clydagh Sep. 10 at 11:29 AM

$TRIB the only thing we know that is about to happen is the vote - which the company stresses is very important to its future - to issue more shares for cash. Now I cannot see them issue new shares at the current price so it seems certain a reverse split has to happen first. Someone pointed out Trib said they would be operationally cash positive in Q3 and so you might ask why would they need a rights issue? They are capitalising CGM related R&D spend - so they can be operationally cash positive but still cash negative overall. TRIB also said "the Group has planned significant R&D expenditure related to its CGM development program in the second half of 2025 and during 2026". Significant expenditure needs significant cash. My guess is that a lot of that CGM related R&D spend is for an FDA approval trial which is a good thing. So whether we like it or not we have a right issue early Oct almost certainly in conjunction with a reverse split. Will need Q2 results and outlook first.

1 · Reply

Trinity Biotech Regains Compliance with Nasdaq Listing Requirements

Aug 21, 2025, 9:00 AM EDT - 22 days ago

Trinity Biotech Appoints Paul Tivnan as Non-Executive Director

Aug 20, 2025, 9:00 AM EDT - 23 days ago

Regulatory Approval Granted for Commencement of Trinity Biotech's Offshored and Outsourced Manufacturing of its Flagship Rapid HIV Test, Facilitating Strategic and Financial Performance Transformation

Aug 14, 2025, 9:00 AM EDT - 4 weeks ago

Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service

Aug 12, 2025, 8:45 AM EDT - 4 weeks ago

Trinity Biotech Achieves Breakthrough Clinical Trial Results for Redesigned CGM Sensor

Aug 7, 2025, 8:00 AM EDT - 5 weeks ago

Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service

Jul 24, 2025, 8:20 AM EDT - 7 weeks ago

Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable Market

Jul 1, 2025, 9:00 AM EDT - 2 months ago

Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround

Jun 24, 2025, 8:00 AM EDT - 2 months ago

Trinity Biotech Secures Key Regulatory Approval for Offshored and Outsourced Manufacturing of Its Flagship Rapid HIV Test, Accelerating Strategic & Financial Performance Transformation

May 15, 2025, 4:00 PM EDT - 4 months ago

Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

Mar 14, 2025, 4:30 PM EDT - 6 months ago

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

Mar 13, 2025, 7:30 AM EDT - 6 months ago

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Feb 28, 2025, 8:30 AM EST - 7 months ago

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

Feb 6, 2025, 7:30 AM EST - 7 months ago

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Jan 28, 2025, 7:20 AM EST - 8 months ago

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Dec 24, 2024, 8:33 AM EST - 9 months ago

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Dec 18, 2024, 11:00 AM EST - 9 months ago

Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

Nov 15, 2024, 12:37 PM EST - 10 months ago

Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript

Nov 15, 2024, 9:00 AM EST - 10 months ago

Trinity Biotech Announces Q3 2024 Financial Results

Nov 14, 2024, 8:07 AM EST - 10 months ago

Trinity Biotech to Announce Q3 2024 Financial Results

Oct 25, 2024, 8:45 AM EDT - 11 months ago

Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform

Oct 25, 2024, 8:45 AM EDT - 11 months ago

Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture

Oct 7, 2024, 8:15 AM EDT - 1 year ago

Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer

Sep 9, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Provides an Update on the Continued Development of Its Continuous Glucose Monitor Technology

Sep 3, 2024, 9:55 AM EDT - 1 year ago

Trinity Biotech Appoints Global Life Sciences Leader as Chief Commercial Officer

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance For 2024 Sales

Aug 20, 2024, 5:00 PM EDT - 1 year ago

Trinity Biotech Appoints Diabetes Care Veteran as Biosensor Marketing Director

Aug 16, 2024, 3:43 AM EDT - 1 year ago

Trinity Biotech plc (TRIB) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:30 AM EDT - 1 year ago

Trinity Biotech Announces Q2 2024 Financial Results

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech to Announce Q2 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements

Aug 2, 2024, 9:24 AM EDT - 1 year ago

Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience

Jul 9, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech Announces Appointment of A New CFO

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor

Jun 10, 2024, 9:10 AM EDT - 1 year ago

Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association

Jun 3, 2024, 4:00 AM EDT - 1 year ago

Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology

May 23, 2024, 6:44 PM EDT - 1 year ago

Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript

May 23, 2024, 8:00 AM EDT - 1 year ago

Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance

May 21, 2024, 4:05 PM EDT - 1 year ago

Trinity Biotech plc to Announce Q1 2024 Financial Results

May 16, 2024, 9:18 AM EDT - 1 year ago

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

May 13, 2024, 11:42 AM EDT - 1 year ago

Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales

May 8, 2024, 10:36 AM EDT - 1 year ago

Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development

Apr 4, 2024, 3:03 PM EDT - 1 year ago

Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates

Mar 28, 2024, 6:39 PM EDT - 1 year ago

Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results

Mar 8, 2024, 10:03 AM EST - 1 year ago

Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Feb 15, 2024, 12:34 PM EST - 1 year ago

Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change

Feb 13, 2024, 9:00 AM EST - 1 year ago

Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change

kd1313 Sep. 12 at 1:27 PM

$TRIB wild to think that Perceptive Advisors is willing to allow share dilution and the inevitable stock split.

0 · Reply

LosersMakeMillions Sep. 12 at 12:35 PM

$TRIB

0 · Reply

EDayTrade Sep. 12 at 12:00 PM

$TRIB 😡😩😡

0 · Reply

Clydagh Sep. 12 at 9:11 AM

1 · Reply

kd1313 Sep. 12 at 7:32 AM

$TRIB

1 · Reply

kd1313 Sep. 11 at 9:00 AM

$TRIB share dilution is going to be approved. Standby for the r/s.

1 · Reply

Think_Bigly Sep. 11 at 4:24 AM

0 · Reply

m1ster_leboeuf Sep. 10 at 9:55 PM

$TRIB Do it.. boom.

0 · Reply

Think_Bigly Sep. 10 at 8:29 PM

0 · Reply

Clydagh Sep. 10 at 11:29 AM

1 · Reply

kd1313 Sep. 10 at 7:58 AM

$TRIB mass share dilution coming. Once a low float not anymore.

0 · Reply

Think_Bigly Sep. 10 at 3:33 AM

$TRIB 300% spike on PreeClamp launch.. 8-14-2025 - Prostate next.

0 · Reply

Think_Bigly Sep. 10 at 3:26 AM

$TRIB The Company is also continuing to progress towards commercialisation on its pipeline of key medium term strategic growth drivers currently under development, including its innovative: **preeclampsia screening test, and **prostate cancer test.

0 · Reply

Think_Bigly Sep. 10 at 3:24 AM

$TRIB The Company also continues to focus on near term opportunities for profitable growth, underpinned by its new, leaner and more scalable operating foundation, with the continued international roll out of its most recently launched products including: its upgraded diabetes care HbA1c testing product, and *additional launch countries* for its TrinScreen HIV tests.

0 · Reply

elmono Sep. 9 at 8:11 PM

$TRIB just wondering how many trading morons actually do DD: “ -Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going forward, reflecting continued strong execution on its comprehensive transformation plan.- - The Company now expects to be meaningfully Adjusted EBITDA1 -positive and cashflow positive from ongoing operating activities, starting Q3 2025 and into the foreseeable future.-“ No brainer

1 · Reply

Clydagh Sep. 9 at 12:18 PM

$TRIB worth reading the Annual Report released yesterday. Some stuff in there i had forgotten about and some things I had not read or heard before.

0 · Reply

Think_Bigly Sep. 9 at 5:06 AM

$TRIB

0 · Reply

Think_Bigly Sep. 9 at 4:55 AM

$TRIB Look at those HIV numbers. Millions.. all headed for the EU, where they will likely gain some pricing power.

0 · Reply

Think_Bigly Sep. 9 at 3:21 AM

$TRIB Yep. 15 minutes after they sell IMMCO.. or get an FDA approval** on their non-invasive test for monitoring aggressive prostate cancer.. or get an 8-10M HIV order.. or the new Sjogren Panel blows up.

1 · Reply

kd1313 Sep. 9 at 2:28 AM

$TRIB Don’t invest in this garage. Share increase will get approved and spilt will come soon enough. Rise and repeat. Poor management.

0 · Reply

Think_Bigly Sep. 9 at 12:33 AM

$TRIB they did issue shares, but they kept us from far worse.. and you could have sold the week before, they warned, or after.. U R FOS. Wake up, you'll see this is a biotech.

0 · Reply

kd1313 Sep. 8 at 9:53 PM

$TRIB backstabbing company that f*cks shareholders. Issue shares and spilt.

1 · Reply

Market Cap	4.19M
Revenue (ttm)	61.56M
Net Income (ttm)	-31.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-51.64%
Debt to Equity Ratio	-1.82

Volume	169,800
Avg Vol	5,553,598
Day's Range	N/A - N/A
Shares Out	3.61M
Stochastic %K	27%
Beta	0.95
Analysts	Hold
Price Target	$15.00